{"id":58873,"date":"2024-02-28T05:32:25","date_gmt":"2024-02-28T05:32:25","guid":{"rendered":"https:\/\/medsname.com\/biodib-30\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"biodib-30","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/biodib-30\/","title":{"rendered":"Biodib 30"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Biodib 30?<\/h3>\n<p style=\"margin:0;\"><strong>Biodib 30<\/strong> este o marc\u0103 a <strong>pioglitazon\u0103<\/strong> (30 mg), a <strong>tiazolidindion (TZD)<\/strong> utilizat pentru tratarea <strong>diabetului de tip 2<\/strong>. Ac\u021bioneaz\u0103 prin activarea receptorilor PPAR-\u03b3, f\u0103c\u00e2nd celulele musculare, adipogene \u0219i hepatice mai sensibile la insulin\u0103 \u2014 abordeaz\u0103 direct rezisten\u021ba la insulin\u0103, nu for\u021beaz\u0103 producerea de insulin\u0103 suplimentar\u0103. Avantaje unice: reducere semnificativ\u0103 a HbA1c (1,0\u20131,5 puncte), control glicemic durabil, efecte favorabile asupra lipidelor \u0219i beneficii cardiovasculare dovedite la pacien\u021bii cu accident vascular cerebral sau infarct miocardic anterior (<em>IRIS<\/em>, <em>PROactive<\/em> studii). Compromisuri: cre\u0219tere \u00een greutate (2\u20134 kg), reten\u021bie de lichide \u0219i risc u\u0219or crescut de fractur\u0103 la femei. Dozare o dat\u0103 pe zi. Evita\u021bi \u00een insuficien\u021b\u0103 cardiac\u0103 (NYHA clasa III\u2013IV), cancer vezical activ \u0219i afec\u021biuni hepatice severe. Nu este pentru diabetul de tip 1.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">Ce este Biodib 30?<\/h2>\n<p>Biodib 30 este un medicament antidiabetic oral care con\u021bine <strong>pioglitazon\u0103<\/strong> (30 mg), fabricat de un produc\u0103tor certificat WHO-GMP. Acesta apar\u021bine clasei de <strong>tiazolidindionice (glitazon\u0103)<\/strong> \u0219i este utilizat pentru adul\u021bii cu diabet zaharat de tip 2 \u2014 fie singur, fie \u00een combina\u021bie cu metformin\u0103, o sulfoniluree, insulin\u0103 sau agen\u021bi mai noi. Disponibil \u00een cutii de 30, 60, 90 sau 180 de comprimate.<\/p>\n<p>Pioglitazona este singurul TZD \u00eenc\u0103 utilizat pe scar\u0103 larg\u0103 (rosiglitazona a fost restric\u021bionat\u0103 \u00een multe \u021b\u0103ri \u00een 2010). Este deosebit de util\u0103 pentru pacien\u021bii cu <strong>rezisten\u021b\u0103 la insulin\u0103<\/strong>, sindrom metabolic sau boal\u0103 hepatic\u0103 gras\u0103 non-alcoolic\u0103 (NAFLD\/NASH).<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Biodib 30?<\/h2>\n<p>Pioglitazona activeaz\u0103 <strong>receptorul nuclear activat de proliferatorii peroxizomilor gamma (PPAR-\u03b3)<\/strong>, un receptor nuclear care regleaz\u0103 expresia genic\u0103 \u00een \u021besutul adipos, mu\u0219chi \u0219i ficat. Acest lucru schimb\u0103 modul \u00een care organismul utilizeaz\u0103 insulina:<\/p>\n<ul>\n<li><strong>Reduce rezisten\u021ba la insulin\u0103<\/strong> \u00een mu\u0219chi \u0219i \u021besut adipos, ajut\u00e2nd celulele s\u0103 extrag\u0103 glucoz\u0103 din s\u00e2nge<\/li>\n<li><strong>Reduce produc\u021bia hepatic\u0103 de glucoz\u0103<\/strong><\/li>\n<li><strong>Modific\u0103 depozitarea gr\u0103similor<\/strong> de la depozitele viscerale (metabolic d\u0103un\u0103toare) la cele subcutanate<\/li>\n<li><strong>Cre\u0219te nivelul de colesterol HDL<\/strong>, scade trigliceridele \u0219i reduce moderat LDL-ul mic-dens aterogen<\/li>\n<li><strong>\u00cembun\u0103t\u0103\u021be\u0219te stetoza hepatic\u0103<\/strong> \u2014 pioglitazonul este unul dintre pu\u021binele medicamente cu dovezi de beneficii \u00een NASH<\/li>\n<\/ul>\n<p>Spre deosebire de sulfoniluree, pioglitazonul <strong>nu provoac\u0103 hipoglicemie<\/strong> ca monoterapie. Efectul maxim de sc\u0103dere a glicemiei se dezvolt\u0103 \u00een 8\u201312 s\u0103pt\u0103m\u00e2ni \u2014 este un agent cu ac\u021biune lent\u0103. Reducerea tipic\u0103 a HbA1c: <strong>1,0\u20131,5 puncte procentuale<\/strong>, cu unele dintre cele mai <em>durabile<\/em> efecte de control glicemic dintre toate agen\u021bii orali (studiu ADOPT).<\/p>\n<h2 class=\"wp-block-heading\">Doza \u0219i administrare<\/h2>\n<p><strong>Doza ini\u021bial\u0103:<\/strong> 15 mg sau 30 mg o dat\u0103 pe zi, luate cu sau f\u0103r\u0103 m\u00e2ncare. Titra\u021bi la 30\u201345 mg o dat\u0103 pe zi dac\u0103 este necesar dup\u0103 8\u201312 s\u0103pt\u0103m\u00e2ni. Doza maxim\u0103: 45 mg\/zi.<\/p>\n<ul>\n<li>Doza o dat\u0103 pe zi \u2014 momentul zilei nu este critic, dar alege\u021bi un moment consistent.<\/li>\n<li><strong>Acorda\u021bi 8\u201312 s\u0103pt\u0103m\u00e2ni<\/strong> \u00eenainte de a evalua eficacitatea \u2014 pioglitazonul ac\u021bioneaz\u0103 lent.<\/li>\n<li><strong>Nu este necesar\u0103 ajustarea dozei<\/strong> \u00een insuficien\u021b\u0103 renal\u0103.<\/li>\n<li>Monitoriza\u021bi <strong>ALT<\/strong> la ini\u021biere \u0219i periodic; verifica\u021bi <strong>greutatea<\/strong> \u0219i urm\u0103ri\u021bi apari\u021bia edemelor.<\/li>\n<li>La femeile \u00een v\u00e2rst\u0103 reproductiv\u0103: pioglitazon\u0103 poate restaura ovula\u021bia \u00een SOPC \u2014 discuta\u021bi metodele contraceptive.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p><strong>Frecvente:<\/strong><\/p>\n<ul>\n<li><strong>Cre\u0219terea \u00een greutate<\/strong> \u2014 de obicei 2\u20134 kg (par\u021bial fluide, par\u021bial redistribuire a gr\u0103similor)<\/li>\n<li><strong>Reten\u021bie de fluide \/ edem periferic<\/strong> \u2014 cel mai frecvent motiv pentru \u00eentrerupere; se agraveaz\u0103 atunci c\u00e2nd este combinat cu insulin\u0103<\/li>\n<li>Cefalee, infec\u021bii ale tractului respirator superior, mialgii<\/li>\n<li>Anemie prin hemodilu\u021bie dependent\u0103 de doz\u0103 (sc\u0103dere mic\u0103 a Hb)<\/li>\n<\/ul>\n<p><strong>Pu\u021bin frecvente, dar importante:<\/strong><\/p>\n<ul>\n<li><strong>Insuficien\u021b\u0103 cardiac\u0103<\/strong> \u2014 pioglitazon\u0103 nu provoac\u0103 direct insuficien\u021b\u0103 cardiac\u0103, dar reten\u021bia de lichide poate dezv\u0103lui sau agrava aceast\u0103 afec\u021biune. Evita\u021bi la pacien\u021bii cu NYHA clasa III\u2013IV.<\/li>\n<li><strong>Fracturi osoase<\/strong> \u2014 risc u\u0219or crescut de fracturi ale membrelor distale la femei (risc absolut mic).<\/li>\n<li><strong>Cancer vezical<\/strong> \u2014 cre\u0219tere mic\u0103 absolut\u0103 a riscului la utilizarea pe termen lung a dozelor mari (discutat\u0103; majoritatea meta-analizelor arat\u0103 un semnal marginal sau nesemnificativ). Evita\u021bi la pacien\u021bii cu cancer vezical activ sau hematurie neexplicat\u0103.<\/li>\n<li>Edem macular (rar)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Gemfibrozil<\/strong> \u2014 dubleaz\u0103 nivelurile de pioglitazon\u0103 (inhibi\u021bie CYP2C8). Limita\u021bi pioglitazona la 15 mg\/zi dac\u0103 este co-prescris\u0103.<\/li>\n<li><strong>Rifampicin\u0103<\/strong> \u2014 reduce nivelurile de pioglitazon\u0103 cu p\u00e2n\u0103 la 50%. Efectul clinic poate fi redus.<\/li>\n<li><strong>Insulin\u0103<\/strong> \u2014 reten\u021bie de lichide \u0219i risc de insuficien\u021b\u0103 cardiac\u0103 aditiv. Utiliza\u021bi doze mai mici de pioglitazon\u0103 \u0219i monitoriza\u021bi prezen\u021ba edemului.<\/li>\n<li><strong>Contraceptive orale<\/strong> \u2014 pioglitazonul poate reduce u\u0219or eficacitatea contraceptivei (inducere minor\u0103 a CYP).<\/li>\n<li><strong>Medicamente hepatotoxice<\/strong> \u2014 combina\u021bi cu precau\u021bie; monitoriza\u021bi ALT.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Cine nu ar trebui s\u0103 ia Biodib 30?<\/h2>\n<ul>\n<li>Insuficien\u021b\u0103 cardiac\u0103 (clasa NYHA III sau IV) \u2014 contraindicatie absolut\u0103<\/li>\n<li>Cancer vezical activ sau antecedente de cancer vezical<\/li>\n<li>Hematurie macroscopic\u0103 neexplicat\u0103 \u2014 investiga\u021bi \u00eent\u00e2i<\/li>\n<li>Insuficien\u021b\u0103 hepatic\u0103 sever\u0103 sau ALT &gt; 2,5\u00d7 limita superioar\u0103 normal\u0103<\/li>\n<li>Cetoacidoz\u0103 diabetic\u0103<\/li>\n<li>Diabet zaharat de tip 1<\/li>\n<li>Sarcin\u0103 \u0219i al\u0103ptare<\/li>\n<li>Hipersensibilitate cunoscut\u0103 la pioglitazon<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>P\u0103stra\u021bi Biodib 30 la o temperatur\u0103 sub 30\u00b0C \u00eentr-un loc uscat, \u00een ambalajul original blister. Depozita\u021bi \u00eentr-un loc inaccesibil copiilor.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Este pioglitazonul o alegere bun\u0103 pentru diabetul zaharat de tip 2?<\/h3>\n<p>Pentru pacientul potrivit \u2014 da. Pioglitazonul este deosebit de potrivit pentru persoanele cu rezisten\u021b\u0103 puternic\u0103 la insulin\u0103, sindrom metabolic, NASH\/ficat gras sau antecedente de AVC\/IM (unde a demonstrat beneficii cardiovasculare \u00een studiile IRIS \u0219i PROactive). Este mai pu\u021bin potrivit pentru pacien\u021bii cu risc de insuficien\u021b\u0103 cardiac\u0103, cei preocupa\u021bi de cre\u0219terea \u00een greutate sau femeile postmenopauzale cu risc de fractur\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Biodib 30 poate cauza cre\u0219tere \u00een greutate?<\/h3>\n<p>Da \u2014 \u00een medie 2\u20134 kg. Aproximativ jum\u0103tate este reten\u021bie de fluide; restul este redistribuire a gr\u0103simii subcutanate. Efectul este dependent de doz\u0103. Combinarea cu metformin\u0103 sau un inhibitor SGLT-2 poate compensa par\u021bial cre\u0219terea \u00een greutate.<\/p>\n<h3 class=\"wp-block-heading\">Biodib 30 poate provoca insuficien\u021b\u0103 cardiac\u0103?<\/h3>\n<p>Pioglitazon\u0103 nu provoac\u0103 insuficien\u021b\u0103 cardiac\u0103 <em>de novo<\/em> \u00een inimile structurale normale, dar reten\u021bia de lichide poate dezv\u0103lui sau agrava disfunc\u021bia ventricular\u0103 st\u00e2ng\u0103 preexistent\u0103. Este contraindicat\u0103 \u00een insuficien\u021ba cardiac\u0103 NYHA clasa III\u2013IV. Pacien\u021bii cu simptome mai u\u0219oare sau care folosesc doze mari de insulin\u0103 trebuie monitoriza\u021bi pentru edem \u0219i dispnee.<\/p>\n<h3 class=\"wp-block-heading\">Pioglitazona provoac\u0103 cancer de vezic\u0103 urinar\u0103?<\/h3>\n<p>Dovezile sunt mixte. Datele observa\u021bionale timpurii au sugerat un risc u\u0219or crescut la utilizarea pe termen lung (&gt; 2 ani) \u00een doze mari, dar studiile ulterioare \u0219i meta-analizele au fost mai pu\u021bin consistente. Recomand\u0103ri actuale: evita\u021bi la pacien\u021bii cu cancer de vezic\u0103 activ sau hematurie neexplicat\u0103; discuta\u021bi balan\u021ba risc-beneficiu pentru utilizarea pe termen lung.<\/p>\n<h3 class=\"wp-block-heading\">Biodib 30 poate fi utilizat pentru PCOS sau ficat gras?<\/h3>\n<p>Pioglitazona are dovezi solide \u00een steatohepatita non-alcoolic\u0103 (NASH) \u2014 studiul PIVENS a ar\u0103tat \u00eembun\u0103t\u0103\u021biri semnificative ale histologiei hepatice. Este de asemenea eficient\u0103 \u00een SOP pentru rezisten\u021ba la insulin\u0103 \u0219i ovula\u021bie, de\u0219i metformina este de obicei prima alegere.<\/p>\n<h3 class=\"wp-block-heading\">C\u00e2t dureaz\u0103 p\u00e2n\u0103 v\u0103d rezultate?<\/h3>\n<p>Pioglitazona este un medicament cu ac\u021biune lent\u0103. Glicemia \u00een post scade \u00een 2\u20134 s\u0103pt\u0103m\u00e2ni, dar efectul complet asupra HbA1c dureaz\u0103 8\u201312 s\u0103pt\u0103m\u00e2ni. Nu opri\u021bi tratamentul prematur \u2014 este unul dintre cele mai durabile agen\u021bi orali odat\u0103 ce \u00ee\u0219i face efectul.<\/p>\n<h3 class=\"wp-block-heading\">Unde pot cump\u0103ra Biodib 30 online?<\/h3>\n<p>Pute\u021bi comanda Biodib 30 (30 mg) de la MedsBase \u00een cutii de 30, 60, 90 sau 180 de comprimate. Livr\u0103m \u00een \u00eentreaga lume, cu ambalaj discret \u0219i stoc original de la produc\u0103tori certifica\u021bi WHO-GMP.<\/p>\n<h2 class=\"wp-block-heading\">Medicamente \u00eenrudite pentru Diabet<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/glycomet-sr\/\">Glycomet SR \u2014 Metformin cu eliberare prelungit\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/januvia\/\">Januvia \u2014 Sitagliptin\u0103 (inhibitor DPP-4)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/jardiance-empagliflozin\/\">Jardiance \u2014 Empagliflozin\u0103 (inhibitor SGLT-2)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/forxiga-dapagliflozin\/\">Forxiga \u2014 Dapagliflozin (inhibitor SGLT-2)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/amaryl\/\">Amaryl \u2014 Glimepirid\u0103 (sulfoniluree)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/pioglit-mf-forte\/\">Pioglit MF Forte \u2014 Combina\u021bie de Pioglitazon\u0103 + Metformin\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/diabetes-medication\/\"><strong>Vizualiza\u021bi toate Medicamentele pentru Diabet<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Dezaprobare medical\u0103.<\/strong> Aceast\u0103 pagin\u0103 are doar scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical al unui medic calificat. Pioglitazona este contraindicat\u0103 \u00een insuficien\u021b\u0103 cardiac\u0103 \u0219i cancer vezical activ \u2014 utiliza\u021bi \u00eentotdeauna sub \u00eendrumare medical\u0103, cu monitorizarea func\u021biei hepatice, a greut\u0103\u021bii \u0219i a edemelor.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/zosert\/\">Zosert<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/meftal-p\/\">Meftal-P<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/caberlin\/\">Caberlin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ciplar\/\">Ciplar<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/symbicort-turbohaler\/\">Symbicort Turbohaler<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Men\u021bine nivelul zah\u0103rului din s\u00e2nge<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te sensibilitatea la insulin\u0103<br \/>\n\u2705 Controlul diabetului<br \/>\n\u2705 Reduce nivelul de glucoz\u0103<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te controlul glicemic<\/p>\n<p>Biodib 30 con\u021bine Pioglitazon\u0103.<\/p>","protected":false},"featured_media":58874,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[4587,4297],"class_list":{"0":"post-58873","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-biodib","11":"product_tag-pioglitazone","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/58873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=58873"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/58874"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=58873"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=58873"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=58873"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=58873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}